Is Pulmonary Medication Adherence affected by disease severity among adult patients with Cystic Fibrosis?
E. Hatziagorou (Thessaloniki, Greece), K. Manika (Thessaloniki, Greece), S. Kyrvasili (Thessaloniki, Greece), E. Kouroukli (Thessaloniki, Greece), E. Sourla (Thessaloniki, Greece), I. Lialias (Thessaloniki, Greece), S. Kotoulas (Thessaloniki, Greece), M. Sionidou (Thessaloniki, Greece), J. Kioumis (Thessaloniki, Greece), J. Tsanakas (Thessaloniki, Greece)
Source: Virtual Congress 2020 – Clinical monitoring and new therapies for cystic fibrosis
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
E. Hatziagorou (Thessaloniki, Greece), K. Manika (Thessaloniki, Greece), S. Kyrvasili (Thessaloniki, Greece), E. Kouroukli (Thessaloniki, Greece), E. Sourla (Thessaloniki, Greece), I. Lialias (Thessaloniki, Greece), S. Kotoulas (Thessaloniki, Greece), M. Sionidou (Thessaloniki, Greece), J. Kioumis (Thessaloniki, Greece), J. Tsanakas (Thessaloniki, Greece). Is Pulmonary Medication Adherence affected by disease severity among adult patients with Cystic Fibrosis?. 368
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: